NEW YORK , April 27 (GenomeWeb News) - Becton Dickinson today reported $1.4 billion in total fiscal second-quarter revenues, a 9-percent increase from the same quarter one year ago.
Revenues were up across BD's Medical, Diagnostics, and Biosciences segments, and BD attributed further revenue increase to foreign currency translation, particularly the euro.
Diagnostics led the growth with a 12-percent increase over the comparable period last year, while Biosciences and medical grew by 9 percent and 8 percent respectively.
R&D spending in the quarter rose to $66 million from $60.2 million in the second quarter of 2004.
Net earnings increased to $188 million, or $.74 per basic share, from $165 million, or $.65 per share, during the second quarter of FY'05.
Cash and cash equivalents were not provided.